Thursday, 4 June 2020

Apheresis Market Shares Analysis, Key Development Strategies And Forecasts Till 2025

Market Research Future Published a Half-Cooked Research Report on Therapeutic apheresis Market Research Report.
Market Scenario
The global apheresis market is presumed to register 10.2 % CAGR during the forecast period (2017-2023), owing to the increasing prevalence of chronic renal diseases, asserts Market Research Future (MRFR). Apheresis is referred to as the procedure of separating and purifying the blood for treating several renal, neurological, autoimmune, hematological, and other diseases. Apheresis involves removal of the blood from the donor or patients and collecting it into an apparatus which separates the component from the blood. The rest of the blood is sent to the patients or the donors. The separation is mainly done using filtration and centrifugation.
Drivers and Constraints Impacting the Market
With the growing prevalence of chronic renal diseases and blood-related diseases, the global apheresis market is considered to stimulate during the estimated period. Increasing complex surgical procedures, rising demand for different component of blood, and growing number of accidents across the globe are considered to augment the market growth in the coming years. Demand for platelets and plasma has also increased which is further impacting the global market positively. Moreover, with continuous advancement in technology and growing need for advanced and automated devices, the market is likely to foster.
On the flip side, high cost of procedures and lack of skilled professionals are some of the major factors considered to impede the market growth in the coming years.
Global Apheresis Market: Segmental Analysis
The global apheresis market has been segmented on the basis of product, procedure, methods, application, end-users, and region.
By mode of product, global apheresis market has been segmented into devices and disposables. The devices segment has been further sub-segmented into platelets separators, plasma separators, and others.
By mode of procedure, the global apheresis market has been segmented into leukapheresis, plateletpheresis, plasmapheresis, erythrocytapheresis, and others.
By mode of methods, the global apheresis market has been segmented into filtration and centrifugation. Among these, centrifugation is further sub-segmented into intermittent flow centrifugation, continuous flow centrifugation, and others.
By mode of application, the global apheresis market has been segmented into oncological diseases, immunological diseases, hematological diseases, cardiovascular diseases, renal diseases, neurological diseases, and others.
By mode of end-users, the global apheresis market has been segmented into hospitals, blood banks, and others.
Regional Insights
Geographically, apheresis market span across regions namely, America, Europe, Asia Pacific, and Rest-of-the-World (RoW).
Among all the regions, America is considered to hold the largest position in the global market and is expected to maintain its dominance during the assessment period. The growth is attributed to the advancement in technology and growing opportunity for apheresis products coupled with the presence of a huge patient population suffering from chronic diseases.
Asia Pacific is considered to be the fastest growing region in the global market owing to the growing demand for blood components for patients. Moreover, rapid development in the healthcare industry along with growing expenditure on health care is considered to contribute to the growth of the global market.
Industry Updates
January 2018: MedAware Systems Inc. has recently launched a comprehensive database on apheresis through its SOHInfo division, carrying data from clinical trials, medical journals, cohort studies, and others.
Competitive Dashboard
The major players operating the global market are Kaneka Corporation (Japan), Terumo BCT Inc. (US), Fresenius Medical Care (Germany), Nikkiso Co. Ltd. (Japan), Asahi Kasei Medical Co. Ltd. (Japan), B. Braun Melsungen AG (Germany), Nikkiso Ltd. (Japan), HemaCare Corporation (US), Cerus Corporation (US), Haemonetics Corporation (US), Kawasumi Laboratories Inc. (Japan), Therakos, Inc. (U.S.), and others.

Posted by at No comments:

Menstrual Cup Market Professional Overview 2019-2025 With Major Vendors Size, Shares And Worldwide Demand

Market Scenario
The menstrual cup industry is predicted to expand at 3.50 % CAGR over the assessment period (2018-2023 due to the growth in women population, asserts Market Research Future (MRFR). An eco-friendly alternative to tampons and sanitary pads, menstrual cup is derived from medical-grade silicone. It is a female sanitary product that comes in the form of a bell-shaped cup and can be inserted into the vagina during menstruation. Such cups prevent leakage of menstrual fluids which makes it highly convenient.
Drivers and Restraints Impacting the Market
Menstrual cup possess a lifespan ranging from 1-10 years and is one of the most affordable solutions for female hygiene. They are reusable, thus making their demand high. With the growing awareness regarding menstrual cups among the female population, availability of a variety of cups with different sizes, and increasing campaigns conducted by the educational institutes, manufacturers, and the women community are considered some of the major factors propelling the market growth. Government is taking initiatives to educate women about hygiene. Also, the guidelines to use the cup is triggering the product demand in the global market. For example, in 2015, South Africa launched Serithi Campaign which aimed to address the issues faced by young girls the during menstrual cycle.
On the flip side, conservative societies have a low-level acceptance of such products which is expected to retard the market growth in the coming years. Also, tough competition faced from other menstrual product manufacturers can inhibit the market growth.
Global Menstrual Cup Market Segmentation
The market is segmented on the basis of type, product, and distribution channel.
By mode of product, the market is segmented into disposable menstrual cup and reusable menstrual cup. Reusable menstrual cup is presumed to dominate the market during the forecast period. The growth can be attributed to the reusability cycle of these cups which ranges from 1 to 5 years. Moreover, these products are cost-effective and eco-friendly which makes them highly demanding.
By mode of type, the market is segmented into pointy, hollow, flat, and round. Among these, the round menstrual cups account for 43 % of the market share due to the flexible design of such products.
By mode of distribution channel, the market is segmented into retail outlets, online stores, and others. Among these, online store channels account for 62 % of the market share due to penetration of e-commerce stores.
Regional Insights
America is presumed to lead the global menstrual cup market during the assessment period. Programs conducted by the government to create awareness among the consumers is likely to propel the market growth. Also, with the presence of major manufacturers such as LENA Cup and Diva International are likely to propel the market growth.
European is predicted to lead the global market owing to the presence of established players. Also, with the increasing health care cost, the demand for menstrual cup is estimated to trigger in this region.
Asia Pacific is presumed to be the third largest market and registers a steady growth in the healthcare sector. The major contributors are Japan, India, China, the Republic of Korea, and Australia. The market is likely to expand owing to the several awareness programs conducted by the organizations and the government in this region.
Industry News
Loon Labs has created reusable cups which tracks the color and volume of the menstrual fluid. It is the world’s first Bluetooth connected menstrual cup which offers women with analytics and tools to monitor their bodies by using metrics.
Competitive Analysis
As the market continues to propel, it is becoming highly fragmented with the presence of local vendors and established players. The major players operating the global market are Diva International Inc., Vcup, Anigan, Ruby Life Ltd., LadyCup, FemCap Inc., Me Luna, The Keeper Inc., Irisana S.A., and Lunette
Posted by at No comments:

Worldwide Ureteral Stents Market Segmentation And Analysis By Recent Trends And Growth Prospects By Regions To 2025

Market Analysis
Ureteral stents are hollow & thin tubes that are inserted in ureters to treat or prevent obstacles during ‘urine-flow.’ They find applications in urological surgeries for retaining ureter patency & ensuring proper urinary-drainage. Ureteral stents are employed by the right end-users through various endourological procedures. They are mainly inserted with the help of cytoscopes. Multiple factors; like kidney stones, prostate cancers, and pre-operative patients draw the adoption of ureteral stents.
These stents enable the transport of remaining fragments without causing obstructions. Stents are also used for scratched ureters. Frankly, any kind of ureter surgery normally involves stents for ureter-treatments. Some other propellers of the ureteral stents market include tumors, bladder irregularities, & ureteral scarring/narrowing. With a rise in such cases, the global ureteral stents market is set to grow at a substantial CAGR in the forecast period.
Propellers & Drawbacks
The ureteral stents market is mainly driven by all medical conditions that need these tubes. The world is experiencing a rise in kidney stones, because of certain factors. These factors encompass regular consumption of alcohol, animal proteins, calcium, vitamin supplements, etc. Of the different ‘kidney-stone’ treatments available, ureterorenoscopy & ureteroscopy observe the widest adoption of these stents, thereby driving the industry.
Alongside, kidney transplants propel market demand. All kidney replacement surgeries require ureteral stents inside the human body, till patients adjust to their new kidneys. Infection, dislocation, & obstruction complexities may result from the adoption of urinary stents, negatively impacting the market. Also, patients could experience discomfort or other problems while passing urine. All these factors urge research & development firms to create new products, slowing down the market.
Inactive lifestyles and aging population are important contributors to urinary disorders. Thus, both of them add to the usage of these stents, promoting market sales. Other factors affecting the market comprise unhealthy food, metabolic disorders, obesity, and dehydration. Novel smartphone applications are advantageous for doctors & patients, raising market expansion. Other hindrances that prevent further industry-progress are scarcity of proficient doctors and intricacies across extractions & placements.  
Classification and Regional Overview
The worldwide market is classified into materials, kinds, applications, and regions. Silicon, metal, hydrogel, plastic, polyurethane, etc. form the materials. The kinds encompass closed end, double pigtail, open end, and multiloop. Based on applications, the market consists of lithotripsy, ureterorenscopy, and others. Latin America, North America, Eastern Europe, Asia Pacific, Western Europe, and the Middle East & Africa constitute the geographies.
Emerging markets, such as Europe and North America are predicted to undergo swift expansion. Their increasing participants, research & developments, and urology incidences drive their sales. Asia Pacific would observe decent trends, as a consequence of its expanding medical infrastructure & supportive ‘patient-demographics.’  Asia Pacific is home to even more patients suffering from these diseases. With better fiscal conditions in India, China, and Brazil; majority of the business expansion could be ascribed to the collective demand from these nations. The Middle East specializes in advanced urology services.
Players and New Trends 
Prominent firms investing in the global ureteral stents market are Urovision, Allium Medical Solutions, Urotech, Teleflex, Mednova, and several others. Multiple advancements with regards to the design & growth of ureteral stents have seen the light of day. These innovations are aimed at lowering stent-related ‘side-effects.’  Some of these include infections, irritability, and bladder discomfort.
‘Bard Medical’ is another renowned manufacturer that helps medical experts in ureteroscopic, cystoscopic, & nephroscopic methods. The past years have witnessed design changes in the form of drug-eluting stents, drug-coated stents, and localized stenting. Thus, many of the eminent companies focusing on product innovations and regional expansion are bound to generate higher revenues & recognition.    

Posted by at No comments:

Global DPT vaccine Market Recent Trends, Growth Opportunities, Forecast By Application And Types To 2027

Market Research Future published a Half – Cooked research report on “Global DPT vaccine Market Research Report – Forecast to 2027” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2027.                                                                                                         
Global Diphtheria Tetanus and Pertussis (DPT) vaccine Market - Overview
The Global Diphtheria Tetanus and Pertussis Vaccine (DPT) vaccine Market is growing exponentially owing to rising prevalence of chronic disease and increasing usage of combination vaccine and therapy are the major factor driving the DPT vaccine Market. Globally the market for DPT vaccine market is expected to grow at the rate of about 7.3% CAGR from 2016 to 2027.
There is an increase in demand of diphtheria tetanus and pertussis vaccine across the globe and rising awareness regarding prevention of diphtheria, tetanus, and pertussis is major factors which are responsible for the growth of this market. The market is expected to show large opportunities in the coming future with the advancement of technology in developing countries and new products with increased accuracy.
Diverging product markets can be seen in preferences for traditional vaccines such as DTP. According to WHO, developed countries prefer to purchase a component of the DPT vaccines such as procure acellular pertussis (DTaP), while most developing countries purchase vaccines with whole cell pertussis (DTwP) components.
However, some of the challenges which the market is expected to face includes competition from new entrants or big pharmaceutical giants entering the business or market and the continuous advancements in the product. Furthermore there are some hindering factors which are restricting the market growth such as side effects and complications during inhalation, high prices of devices, and lack of accuracy etc.
Global DPT vaccine Market - Regional Analysis
Globally, DPT Vaccine market consists of four regions North America, Europe, Asia-Pacific and Middle East and Africa.  North America is the largest market for diphtheria tetanus and pertussis vaccine (DPT) vaccine.
The North American market for DPT Vaccine is expected to grow steadily over the forecasted period. This is due to the presence of high concentration of major market players in North America and its emphasis on vaccination against DPT. North American market consists of countries like the U.S., Canada and Mexico. Death rate sue communicable disease is seen to be growing, thus highlighting the importance of immunization. For instance, In March 2015 U.S FDA approved the use of Quadracel for immunization of children from 4 to 6 years of age. This was a great achievement for Sanofi helping it to maintain its leading position in the market.
Europe is the second-largest market for DPT Vaccine which is expected to grow at an overwhelming CAGR during the forecast period. This is due to increasing research and development activities by pharmaceutical companies and research institutes. The market is growing continuously in Europe as the key market players invested huge financial resources on research and development activities for the production of effective vaccines.  Increasing awareness about immunization of children against Diphtheria, tetanus and pertussis also drive this market in Europe.
Moreover, Asia Pacific is expected to be the fastest growing market for DPT Vaccine market. India is expected to be the emerging and fastest growing market. Presence of large patient pool drive this market in Asia-pacific. This region is expected to grow at a higher rate due to rapid population growth, increase in adoption for vaccination, and growth in prevalence of infectious disease. Governments in developing countries of Asia-Pacific have undertaken various vaccinations programs. National Health Mission in India provide vaccination against diphtheria, pertussis, tetanus and polio.
The market shows steady growth in Middle East and Africa. In Middle East and Africa the demand for DPT vaccine is less than other regions across the globe.
Global DPT vaccine Market - Company Analysis
Merck: Merck provides a wide range of vaccines which includes BCG USP, Pneumonix, Varivax, Pedvax HIB, Recombivax HB and others.
Sanofi: Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care. From prevention to treatment, Sanofi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions, consumer healthcare, established prescription products and generics. Diphtheria and Tetanus Toxoids and acellular Pertussis Vaccine called Daptacel is the product offered by Sanofi which is the major market player.
Merck & Co., Inc (U.S), Sanofi (France), GSK (U.S), Lanzhou Institute of Biological Products (China), Wyeth (U.S), Chiron Pharmaceutical Pvt Ltd (India), Serum Institute of India Pvt. Ltd. (India), Lanzhou Institute of Biological Products (China) and others are some of the prominent players at the forefront of competition in the Global DPT vaccine Market and are profiled in MRFR Analysis. 
Posted by at No comments:

Biosimilars Market Likely Boost The Industry Revenue And Demand Till 2025

Biosimilars Market Size is expected to register a CAGR of 7.5% during the forecast period of 2019 to 2025, with a market value of USD 13,460 Million in 2018.
A biosimilar is a biologic medical product highly similar to another already approved biological medicine. Biosimilars are approved according to the same standards of pharmaceutical quality, safety, and efficacy that apply to all biological medicines. The global biosimilars market is driven by factors such as rising demand for biosimilars due to their cost-effectiveness and growing prevalence of chronic diseases. Additionally, rising pressure to reduce healthcare expenditure coupled with patent expiry of various blockbuster drugs and the increasing number of biosimilar drug approvals by the FDA is anticipated to fuel the Biosimilars market trends growth.
 For instance, according to the biosimilars update report by Amgen in 2019, As of January 2019, the US Food and Drug Administration (FDA) approved 17 biosimilars, out of which 7 products launched in 4 therapeutic areas. On the other hand, patient safety and medical efficacy are projected to hamper the growth of the market during the assessment period. Moreover, major companies in the market are involved in strategic acquisitions, collaborations, and mergers to sustain their position in the market.
For instance, in October 2018, Sandoz, a Novartis division received the US Food and Drug Administration (FDA) approval for its biosimilar, HyrimozTM (adalimumab-adaz) for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PSA),  juvenile idiopathic arthritis (JIA) in patients four years of age and older, ulcerative colitis (UC), ankylosing spondylitis (AS), adult Crohn's disease (CD), and plaque psoriasis (Ps)
Biosimilars Market Segmentation
Global Biosimilars Market has been segmented based on product, applications, end users, and region.
The market, based on product, has been bifurcated into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides.
The recombinant non-glycosylated proteins are further divided into human growth hormone (RHGH), granulocyte colony-stimulating factor (filgrastim), insulin, and interferons. Similarly, the recombinant glycosylated proteins segment is further bifurcated into erythropoietin (EPO), monoclonal antibodies (MABS), and follitropin. The recombinant peptides segment has been subdivided into glucagon and calcitonin
The recombinant non-glycosylated proteins segment is expected to hold a major share in the market due to an increase in the number of incidences of chronic diseases, diabetes also growth hormone deficiency-related disorders. Thus, the therapeutic use of recombinant non-glycosylated proteins is broadening as their increased availability and lowered price.  
For example, according to the International Diabetes Federation (IDF), in 2017, approximately 425 million adults aged between 20 to 79 years suffered from diabetes, and this number is expected to rise to 629 million by 2045.
On the basis of applications, the global biosimilars market has been divided into oncology, chronic diseases, autoimmune diseases, blood disorders, growth hormone deficiency, infectious diseases, and others. Blood disorders segment is expected to grow with high growth rate due to increased prevalence of blood disorders and adoption of biosimilars as its low cost in comparison to biologics reduces the treatment cost.
For example, according to the Centers for Disease Control and Prevention in the US, hemophilia A affects 1 in 5,000 male births, and about 400 babies are born with hemophilia A each year.
Based on end user, the market has been divided into hospitals and clinics is expected to hold the largest share in the market as easy availability for treatment with expert faculties.
Based on region, the global biosimilars market has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The biosimilars market in the Americas has further been segmented into North America and Latin America; the North American market has been further divided into the US and Canada.
The European biosimilars market has been sub-divided into Western Europe and Eastern Europe. Western Europe has further been classified as France, the UK, Germany, Italy, Spain, and the rest of Western Europe. The biosimilars market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The biosimilars market in the Middle East & Africa has been divided into the Middle East and Africa.
Biosimilars Market Key Players
The key players in the Global Biosimilars Market are Pfizer (US), Sandoz International (Germany), Teva Pharmaceuticals (Israel), Amgen, Inc. (US), Biocon (India), Dr. Reddy’s Laboratories (India), Celltrion (South Korea), Samsung Biologics (South Korea), Eli Lily & Company (US), Hospira Inc.(US), Actavis, Inc.(US), Cipla Ltd (India), Stada Arzneimittel AG (Germany), and Mylan, Inc.(US).
Posted by at No comments:

The Erectile Dysfunction Drugs Market Grows Incredibly; Confirms Mrfr Unleashing Industry Prognostications Up To 2025

Market Research Future published a Half Cooked research report on “Global  Erectile Dysfunction Drugs Market Research Report - Forecast to 2023” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2023.
Pfizer Inc. (U.S), Bayer AG (Germany), Eli Lily & Co. (U.S), Dong–A Pharmaceutical Co. Ltd. (South Korea), Apricus Biosciences Inc.(U.S), S.K. Chemicals Co. Ltd. (South Korea), Apricus Biosciences Inc. (U.S), Cristalia Produtos Quimicos Farmaceuticos Ltd. (Brazil), Dong-A Pharmaceutical Co. Ltd., (South Korea), Meda Pharmaceuticals, Inc. (U.S),  Vivus, Inc. (U.S),  and others are some of the prominent players at the forefront of competition in the global erectile dysfunction drugs market and are profiled in MRFR Analysis. 
Global Erectile Dysfunction Drugs Market - Overview
Erectile dysfunction is the inability to attain or maintain penile erection in men, sufficient for successful sexual intercourse. It is also known as impotence. It is a common medical disorder primarily affecting men older than 40 years of age. Growing elderly population, increasing awareness and patient education, elevated inclination towards a sedentary lifestyle, and growing incidence of several genitourinary diseases are some of the factors expected to drive the growth of the global erectile dysfunction drugs market. Management of this disorder includes medical history, sexual history and psychological history of a person. There are number of drugs available for the treatment of erectile dysfunction which include both branded and generic drugs. Over 20 million men all over the world have used or are currently using Viagra to treat erectile dysfunction.
Stress and mental health concerns may worsen the problem of erectile dysfunction. Physical and psychological issues may also cause erectile dysfunction. The market of erectile dysfunction drugs is driven by the number of drugs available in the market and increasing number of men suffering from this disorder. There is also an increase in the competition among the major market players. According to a trials conducted by the American Urological Association (AUA) Consensus Panel on Erectile Dysfunction, 36% to 76% of patients on erectile dysfunction drug were able to achieve intercourse during treatment.
The market for erectile dysfunction drugs is growing rapidly and expected to continue its growth in near future. However, factors such as growing threat from counterfeit drugs, prevalence of STDs in erectile dysfunction drug users, and shrinking insurance coverage for ED treatment will hamper the growth of global erectile dysfunction market. Moreover, patent expiry of number of blockbuster drugs, availability of counterfeit drugs and increasing manufactures of generic drugs in the market may result in the decline of erectile dysfunction drugs market. Global market of erectile dysfunction drugs is expected to reach USD 2.95 billion in 2023 from USD 1.65 billion in 2016 over the forecast period 2017-2023.
The global erectile dysfunction drugs market is expected to grow at a CAGR of 6.5% during the forecast period 2017-2023. 
Global Erectile Dysfunction Drugs Market – Regional:
Geographically, the regional market is segmented into America, Europe, Asia Pacific, and the Middle East & Africa.
The Americas account for the major share of the market owing to the presence of patient population, well-developed technology, and high healthcare expenditure. According to University of Wisconsin Hospitals and Clinics Authority, about 5 percent of men that are 40 years old have complete erectile dysfunction, and that number increases to about 15 percent of men at age 70. Mild and moderate erectile dysfunction affects approximately 10 percent of men per decade of life.
Europe holds the major share of the market, which is majorly contributed by Germany, the U.K., and France. According to the UK Health Centre, 50 percent of men that smoke a pack of cigarettes a day have a higher chance of developing erectile dysfunction. Furthermore, as per a study recently presented at the European Association of Urology showed that erectile dysfunction isn’t being treated very often, with only 25.4 percent of men in the being treated for the condition.
Asia Pacific is the fastest growing market owing to rapidly changing healthcare sector, and the presence of huge opportunities for the development of this market. However, the Middle East & Africa has the least share in the market owing to the presence of poor and slow developing countries, especially, in African region. The Middle East holds the major share of the regional market due to well-developed technology and high spending.
Global Erectile Dysfunction Drugs Market Players:
Pfizer Inc. manufactures Viagra drug for erectile dysfunction treatment. Bayer AG manufactures Levitra drugs for the treatment of erectile dysfunction. Eli Lilly and Company manufactures a drug named Cialis for erectile dysfunction.
For instance, in May 2014, Sanofi and Eli Lilly and Company announced an agreement for regulatory OTC approval of Cialis (tadalafil). Cialis is now available as OTC drug worldwide for the treatment of men with erectile dysfunction (ED).
Posted by at No comments:

Blood Glucose Test Strip Market Strategies And Competitive Analysis, Forecast Till 2025

Global Blood Glucose Test Strip Market Analysis
Blood glucose test strip is a small disposable plastic strip and is an important component of blood glucose meters that monitors and controls diabetes. These strips are impregnated with glucose oxidase, which reacts with glucose present in the blood and then indicate the glucose level in the blood.
The convenience offered by the self-blood glucose testing over the traditional methods is one of the major drivers of the blood glucose test strip market. The self-testing allows the diabetic and the pre-diabetic people to keep a track of their blood glucose level regularly without visiting a clinic or diagnostic laboratory. A diabetic patient is expected to test his sugar at least 2-3 times a day, self-testing allows the patient to perform his test regularly at his home. Rising diabetic population is another major driver of the market. Diabetes is one of the major concerns for the government bodies across the globe. The number of diabetic population across the world is rising continuously. According to the International Diabetic Federation, about 415 million people had diabetes across the globe in 2015, and this number is poised to reach 642 million by 2040. Financial support by the governments is an important economic driver of the market due to its effects on the demand for blood glucose strips. For example, Australian Government is taking various initiatives to increase the usage of blood glucose monitors and test strips.
Browse More Details of the Report @ https://www.marketresearchfuture.com/sample_request/976

The government has implemented Pharmaceutical Benefits Scheme (PBS). According to this scheme, the blood glucose test strips are provided to the Australian at a government-subsidised prices. Moreover, the foreign visitors from the countries such as the U.K., Ireland, New Zealand, Malta, Italy, Sweden, the Netherlands, Finland, Norway, Belgium and Slovenia are also covered under this scheme. The other drivers for blood glucose test strips market are technological advancements such as accuracy of the test, awareness about diabetes, etc. Rising disposable income of emerging economies is another economic driver of the market. For example, annual disposable income of middle class households in India was $1,366.2 billion in 2010, which reached $1,587.6 billion in 2013.
The market restraints are inadequate reimbursement for test strips etc. For example, in March 2013, Medicare announced reimbursement cuts for diabetes testing supplies (DTS) up to 72%. According to new reimbursement policies, diabetic beneficiaries, who receive their glucose-testing supplies delivered to their homes will need to obtain them from 1 of 18 contract suppliers chosen by Medicare via a competitive bidding process. This new plan will help the government to reduce healthcare expenditure. However, it can drastically reduce the number of vendors from which diabetic patients can obtain glucose-testing supplies. Furthermore, this amendment can also lead to disruption in the supplies of blood glucose monitoring accessories, which could result into decline in self-monitoring of glucose and subsequent adverse outcomes.
The global big data in the blood glucose test strips market is expected to reach US$ 18.5 billion by 2020, and the market is projected to grow at a CAGR of ~ 6.2 % during the forecast period 2015-2020.
Key Findings:
  • In 2015, Thick Film Electrochemical strips generated the largest revenue of $ 6.4 billion by technology
  • Thin Film Electrochemical segment generated revenue of US$ 5 billion in 2015 by technology
  • North America accounted for the largest revenue of US$ 7.89 billion for blood glucose test strips in 2015, by geography
Segments
The global blood glucose test strip market has been segmented on the basis of technology. On the basis of technology the market has been segmented into thick film electrochemical, thin film electrochemical, and optical.Regional analysisThe Americas holds a significant market share of the global market owing to extensive use of information technology and high expenditure on the health care. Additionally, the fastest uptake of new technology and the presence & concentration of medical device manufacturers in the US regions drive the blood glucose test strip market.
North America led the global blood glucose test strip market with revenue of $ 7.89 billion in 2015.
Europe is the second largest market in the globe due to a high healthcare expenditure, which is led by Germany and France.
Asia Pacific region is expected to grow rapidly; China and India are likely to lead the market due to unmet needs during the forecasted period. APAC is expected to grow at a higher CAGR of 12.9 % than the other regions because of increasing number of diabetic population in this region.
Gulf nations such as Saudi Arabia and the UAE drive the Middle East & African market. The African region is expected to witness a moderate growth owing to poor economic & political conditions and poor healthcare development.
Key Players in the Global Blood Glucose Test Strip Market
Some of key players profiled in the report are Abbott, Roche Diagnostics, LifeScan, i-SENS, Bayer Diabetes Care, AgaMatrix Inc, Elektronika, Universal Biosensors, Nipro Diagnostics, TaiDoc, Apex Biotechnology Corp, B. Braun, HMD BioMedical Inc., ALL Medicus, SANNUO, Beijing Yicheng Electronics, Betachek National Diagnostics, Shanghai MicroSense, Jiangsu Yuyue, ACON Laboratories and others.
Posted by at No comments:
Subscribe to: Posts (Atom)